Speaker

Eric Fischer, Ph.D. is the Director of the Chemical Biology Program at Dana-Farber Cancer Institute, Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, Director of the DFCI Center for Protein Degradation, and Co-Director of the Center for Therapeutics Discovery. Dr. Fischer trained in structural biology and biochemistry at the University of Basel and conducted his doctorate studies at the Friedrich Miescher Institute for Biomedical Research. During his graduate work, he has been recognized for pioneering work on the mechanism of action of thalidomide. His lab at Dana-Farber focusses on the understanding of fundamental processes in ubiquitin signaling, and the molecular basis of ubiquitin ligase activity, targeting and regulation. His lab seeks to leverage this understanding for the development of novel therapeutic approaches, such as targeted protein degradation. He and his lab have significantly contributed to our understanding of small molecule mediated protein degradation, and its widespread application in academia and industry. Dr. Fischer has co-founded Civetta Therapeutics, Proximity Therapeutics and Neomorph and serves on the scientific advisory board for the Institute for Protein Innovation, Avilar Therapeutics, Ajax Therapeutics and Photys Therapeutics.

« Go Back